Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while reaffirming the collaboration's support for Phase 3 recruitment in major depressive disorder and alignment with a recent executive order on mental health treatments.
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists, has issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder and expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. In addition to HLP003, Helus Pharma is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder, and has an extensive research portfolio of investigational NSAs.
The correction comes amid a broader push for mental health innovation, with the company noting that its collaboration aligns with a recent executive order focused on improving mental health treatments and increasing clinical research participation. This alignment underscores the potential significance of the partnership in advancing treatment options for veterans and others with major depressive disorder.
For more details on the full press release, visit https://ibn.fm/re8HL. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on social media platforms.
The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.